Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland.
Division of Nephrology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania; Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania.
Am J Kidney Dis. 2023 May;81(5):545-553. doi: 10.1053/j.ajkd.2022.10.009. Epub 2022 Dec 12.
RATIONALE & OBJECTIVE: Accurate detection of hypertension is crucial for clinical management of pediatric chronic kidney disease (CKD). The 2017 American Academy of Pediatrics (AAP) clinical practice guideline for childhood hypertension included new normative blood pressure (BP) values and revised definitions of BP categories. In this study, we examined the effect of applying the AAP guideline's normative data and definitions to the Chronic Kidney Disease in Children (CKiD) cohort compared with use of normative data and definitions from the 2004 Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents.
Observational cohort study.
SETTING & PARTICIPANTS: Children and adolescents in the CKiD cohort.
Clinic BP measurements.
BP percentiles and hypertension stages calculated using the 2017 AAP guideline and the Fourth Report from 2004.
Agreement analysis compared the estimated percentile and prevalence of high BP based on the 2017 guideline and 2004 report to clinic and combined ambulatory BP readings.
The proportion of children classified as having normal clinic BP was similar using the 2017 and 2004 systems, but the use of the 2017 normative data classified more participants as having stages 1-2 hypertension (22% vs 11%), with marginal reproducibility (κ=0.569 [95% CI, 0.538-0.599]). Those identified as having stage 2 hypertension by the 2017 guideline had higher levels of proteinuria compared with those identified using the 2004 report. Comparing use of the 2017 guideline and the 2004 report in terms of ambulatory BP monitoring categories, there were substantially more participants with white coat (3.5% vs 1.5%) and ambulatory (15.5% vs 7.9%) hypertension, but the proportion with masked hypertension was lower (40.2% vs 47.8%, respectively), and the percentage of participants who were normotensive was similar (40.9% vs 42.9%, respectively). Overall, there was good reproducibility (κ=0.799 [95% CI, 0.778-0.819]) of classification by ambulatory BP monitoring.
Relationship with long-term progression and target organ damage was not assessed.
A greater percentage of children with CKD were identified as having hypertension based on both clinic and ambulatory BP when using the 2017 AAP guideline versus the Fourth Report from 2004, and the 2017 guideline better discriminated those with higher levels of proteinuria. The substantial differences in the classification of hypertension when using the 2017 guideline should inform clinical care.
准确检测高血压对于儿科慢性肾脏病(CKD)的临床管理至关重要。2017 年美国儿科学会(AAP)儿童高血压临床实践指南纳入了新的正常血压(BP)值和修订后的 BP 分类定义。本研究旨在评估与使用 2004 年第四次儿童和青少年高血压诊断、评估和治疗报告中的标准数据和定义相比,应用 AAP 指南的标准数据和定义对 CKiD 队列的影响。
观察性队列研究。
CKiD 队列中的儿童和青少年。
诊所血压测量。
使用 2017 年 AAP 指南和 2004 年第四次报告计算的 BP 百分位数和高血压阶段。
比较基于 2017 年指南和 2004 年报告的诊所和联合动态血压读数的估计 BP 百分位数和高血压患病率的一致性分析。
使用 2017 年和 2004 年系统分类为正常诊所血压的儿童比例相似,但使用 2017 年的标准数据将更多的参与者归类为 1-2 期高血压(22% vs 11%),具有边缘可重复性(κ=0.569 [95%CI,0.538-0.599])。与使用 2004 年报告相比,使用 2017 年指南被归类为 2 期高血压的患者蛋白尿水平更高。比较使用 2017 年指南和 2004 年报告在动态血压监测分类方面,白大衣高血压(3.5% vs 1.5%)和动态高血压(15.5% vs 7.9%)的参与者明显更多,但隐匿性高血压的比例更低(40.2% vs 47.8%),血压正常的参与者比例相似(40.9% vs 42.9%)。总体而言,动态血压监测的分类具有很好的可重复性(κ=0.799 [95%CI,0.778-0.819])。
未评估与长期进展和靶器官损害的关系。
与使用 2004 年第四次报告相比,基于诊所和动态血压的 CKD 患儿中更多的患儿被诊断为高血压,且 2017 年 AAP 指南更好地区分了蛋白尿水平较高的患儿。使用 2017 年指南进行高血压分类存在显著差异,这应该影响临床治疗。